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Abstract
Background. In chronic kidney disease (CKD) patients,
the intake of calcium-based phosphate binders is associated
with a marked progression of coronary artery and aortic
calcification, in contrast to patients receiving calcium-free
phosphate binders. The aim of this study was to reexam-
ine the role of calcium carbonate in vascular calcification
and to analyse its effect on aortic calcification-related gene
expression in chronic renal failure (CRF).
Methods. Mice deficient in apolipoprotein E underwent
either sham operation or subtotal nephrectomy to create
CRF. They were then randomly assigned to one of the
three following groups: a control non-CRF group and a
CRF group fed on standard diet, and a CRF group fed on
calcium carbonate enriched diet, for a period of 8 weeks.
Aortic atherosclerotic plaque and calcification were eval-
uated using quantitative morphologic image processing.
Aortic gene and protein expression was examined using
immunohistochemistry and Q-PCR methods.
Results. Calcium carbonate supplementation was effective
in decreasing serum phosphorus but was associated with a
higher serum calcium concentration. Compared with stan-
dard diet, calcium carbonate enriched diet unexpectedly
induced a significant decrease of both plaque (p < 0.05)
and non-plaque-associated calcification surface (p < 0.05)
in CRF mice. It also increased osteopontin (OPN) protein
expression in atherosclerotic lesion areas of aortic root.
There was also a numerical increase in OPN and
osteoprotegerin gene expression in total thoracic aorta
but the difference did not reach the level of significance.
Finally, calcium carbonate did not change the severity of
atherosclerotic lesions.
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Conclusion. In this experimental model of CRF, calcium
carbonate supplementation did not accelerate but instead
decreased vascular calcification. If our observation can be
extrapolated to humans, it appears to question the con-
tention that calcium carbonate supplementation, at least
when given in moderate amounts, necessarily enhances vas-
cular calcification. It is also compatible with the hypothesis
of a preponderant role of phosphorus over that of calcium
in promoting vascular calcification in CRF.
Keywords: atherosclerosis; calcification; calcium
carbonate; CKD; phosphate; uraemia
Introduction
Extensive atherosclerosis and vascular calcification are
common complications of advanced chronic kidney disease
(CKD). They are associated with each other [1] and with
a high incidence of cardiovascular events and mortality.
The factors involved in these complications are complex.
Numerous metabolic and endocrine abnormalities involv-
ing calcium and phosphorus metabolism are found in CKD
[2–4]. Furthermore, CKD is believed to be a state of inflam-
mation and oxidative stress [5–7]. Most of these abnormal-
ities occur early in the course of chronic renal failure (CRF)
and may contribute to the development and progression of
vascular calcification and atherosclerosis [8].
The mechanisms regulating the process of vascular
calcification and the factors involved are subject to con-
tinued investigation. Both calcium and phosphorus directly
stimulate vascular smooth muscle cell transformation into
osteoblast-like cells and abnormal mineralization in vitro
[9–11]. In addition, numerous other factors have been
shown, both in vitro and in vivo [12–15], to promote this
process, in part through the production and activity of
proteins like osteopontin (OPN), osteoprotegerin (OPG),
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osteocalcin, bone morphogenic proteins and matrix Gla
protein [16].
In clinical studies in CKD patients, hypercalcaemia and
hyperphosphataemia have also been found to be associated
with the vascular calcification process [17,18]. The recent
recognition of hyperphosphataemia as a predictor of car-
diac and all-cause mortality [19,20] points to the neces-
sity of phosphate-lowering treatments. This includes the
oral administration of traditional calcium-based phosphate
binders and, more recently, of calcium-free compounds such
as sevelamer hydrochloride and lanthanum carbonate. In
three randomized controlled trials in chronic haemodial-
ysis patients, the administration of calcium-based phos-
phate binders was associated with marked progression
of coronary artery and aortic calcification, in contrast to
patients receiving sevelamer treatment [21,22], and with
higher mortality [23]. However, in these studies, it was not
possible to include non treated groupe or histological anal-
yses of vascular calcification such as those which can be
done in animal models.
We decided to address the question of the role of calcium-
containing phosphate binders in arterial calcification and
atherosclerosis in a common model of rapidly progres-
sive atherosclerosis, namely the apolipoprotein E-deficient
(apoE−/−) mouse. When superimposing CRF in this model,
according to a recently established method, severe vascular
calcification occurs spontaneously together with acceler-
ated atheroma progression [24,25]. Extensive aortic cal-
cium phosphate deposits are observed both in atheromatous
plaque (‘intima’) and non-plaque areas (‘media’) [25].
The goal of the present study was to examine in this
mouse model the hypothesis of an acceleration of cardio-
vascular calcification by calcium carbonate, and if so, to
evaluate whether calcium deposits were limited to the non-
plaque areas, plaque areas, or both. We also tested the effect
of CRF and calcium carbonate respectively on aortic gene
expression of OPG and OPN, both involved in the regula-
tion of the vascular calcification process [26,27] and also
on the aortic protein expression of OPN.
Methods
Animals
Female, 8-week-old apoE−/− homozygous mice were ini-
tially obtained from Charles Rivers Breeding Laboratories
(Wilmington, MA, USA) and subsequently bred in our an-
imal facility. Since it has been shown that in 16-week-old
apoE−/− mice, atherosclerotic plaque formation is two to
three times greater in female than in male animals [25], we
used only female mice. All procedures were in accordance
with the National Institutes of Health (NIH) guidelines for
care and use of experimental animals (NIH publication No.
85–23). The mice were housed in polycarbonate cages in a
pathogen-free, temperature-controlled (25◦C) facility, with
a strict 12-h light-dark cycle and free access to standard
diet and water. The powder diet (Harlan Teklad Global Diet
2018, Harlan, UK) contained 18.9% protein, 6% fat, 1.01%
calcium, 0.65% phosphorus, 1.55 calcium/phosphorus ra-
tio and 1.54 IU/g vitamin D3. This is a regular diet which
is widely used in animal facilities and whose phosphorus
content is not high. Calcium carbonate was administered
as a 3% mix, together with the standard diet to one mouse
group for a period of 8 weeks.
Experimental procedure and diet
At the age of 10 weeks, we created CRF in apoE−/− mice
according to a previously reported two-step procedure [25].
Briefly, at the age of 8 weeks, we applied cortical electro-
cautery to the right kidney through a 2 cm flank incision,
and performed left total nephrectomy through a similar
contralateral incision at the age of 10 weeks. Special care
was taken to avoid damage to the adrenals. Other mice
underwent a two-step procedure of sham surgery with de-
capsulation of both kidneys and a 14-day distance between
the two operations. Blood samples were taken 2 weeks af-
ter nephrectomy. Non-CRF mice (20 animals, serum urea,
7–10 mM) were put on standard diet. CRF mice were ran-
domized, based on serum urea levels (>20 mM) to two
experimental groups receiving either standard diet plus 3%
calcium carbonate (CaCO3) supplementation (25 animals)
or standard diet alone (25 animals). The mortality noted
in both the CRF groups was approximately 20%, mostly
due to excessively severe uraemia following the operation.
In order to perform Q-PCR analysis of aortic lesion gene
expression, we did experiments in a supplementary series
of animals undergoing the same experimental procedure
as above. We present the biochemical and tissue analyses
obtained in these two animal series together.
At the end of the study, mice were sacrificed under
anaesthesia with ketamin/xylasine (100 mg/kg, 20 mg/kg)
and whole blood was collected via cardiac puncture. Sub-
sequently, the heart and aorta were dissected and freed
from connective tissues. Dissected aortas were fixed in
4% formaldehyde for quantification of atherosclerotic le-
sions. In the supplementary series of animals, a solution of
phosphate-buffered saline (PBS) was perfused through the
heart and aorta. The aortas were then handled with sterile
surgical instruments, quickly dissected and freed down to
the renal arteries, plunged into RNA-later reagent and kept
for 24 h at 2–8◦C. Finally, they were frozen in RNase-free
tubes at −80◦C and further analysis of gene Q-PCR expres-
sion was performed. In both series of animals, in order to
quantify calcium phosphate deposits and atherosclerotic le-
sion extension and to perform immunohistochemistry anal-
yses at the aortic root site, the aortic roots were separated
from the aortas. The aortic root with three visible valves was
embedded in Optimal Cutting Temperature (OTC) gel un-
der dissecting microscope and stored at −80◦C, as reported
previously [25].
Total RNA extraction from aorta
Aortas were surgically removed and stored at −80◦C prior
to extraction using RNA-later reagent (Qiagen) according
to the manufacturer’s protocol. Aortas were disrupted in
TRI reagent (Sigma Aldrich) using a homogenizer. We then
proceeded as described by the manufacturer’s protocol
till the first centrifugation. After the centrifugation, we
immediately removed the top supernatant and mixed with
0.7-fold volume of absolute ethanol. The mix was
transferred to the microspin column supplied with the
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micro Rneasy total RNA isolation kit (Qiagen). Washing
of the column, DNAse treatment and elution of RNA
were performed using the protocol supplied by Qiagen.
Samples of total RNA were quantified using the standard
OD260 method. RNA quality was confirmed by the ab-
sence of degradation products after denaturing agarose gel
electrophoresis and staining with ethidium bromide.
Serum biochemistry
Blood was sampled via retro-orbital venous sinus punc-
ture at the time of randomization and at 4 weeks of treat-
ment, and subsequently again at 8 weeks of treatment via
cardiac puncture, at the time of sacrifice. The collected
blood was put into chilled dry tubes, spun in a refriger-
ated centrifuge for 10min/100000rpm and stored as serum
at −80◦C. Serum levels of urea, calcium, phosphorus and
total cholesterol were measured using Hitachi 917 auto an-
alyzer (Roche, Meylan, France), as previously described
[25]. Parathyroid hormone (iPTH) was measured using two-
site ELISA for the quantitative determination of mouse in-
tact parathyroid hormone levels in serum (Immutopics, San
Clemente, California, 96 Test Kit, Cat#60–2300).
Quantification of atherosclerotic plaques and aortic gene
expression by reverse transcription reaction and Q-PCR
Evaluation of the atherosclerotic plaque area was made by
‘en face’ method described previously [24,28]. Briefly, the
aortas were carefully freed of connective and adipose tissue
under a dissection microscope, opened longitudinally and
stained with Oil red O. The quantification was made with
Histolab software (Microvision Instruments, Evry, France),
as reported [25]. The extent of atherosclerosis was ex-
pressed as the percentage of surface area of the aorta cov-
ered by lesions. We performed two series of experiments.
In the first series, we examined atherosclerotic plaques in
the thoracic aorta, while in the second series, the thoracic
aortas were used to examine gene expression.
The aortic expression of the selected genes was analysed
by Q-PCR with an ABI prism 7900 HT (Applied Biosys-
tems). The eluted RNA was used in a reverse transcription
reaction. The cDNA was made from 0.5 µg total RNA
from one mouse aorta using high capacity cDNA Archive
Kit (Applied Biosystems) in a 20 µl reaction at 37◦C for
2 h. Q-PCR was done in a 20 µl volume containing 1 µl
of reverse transcription products and 0.5 µmol/l of each
primer, diluted 1:2 with SYBR Green I Master Mix (Ap-
plied Biosystems). The primers and gene product sizes were
5’-tccaatcgtccctacagtcga-3’ and 5’-aggtcctcatctgtggcatca-
3’ (126 bp) for OPN; 5’-aagagcaaaccttccagctgc-3’ and
5’-cgctgctttcacagaggtcaa-3’ (102 bp) for OPG; and 5’-
gggtatggaatcctgtggcat-3’ and 5’-ttcagcatcctgtcagcaatg-3’
(143 bp) for β-actin. All primers were obtained from Euro-
gentec. Amplification by Q-PCR was performed as follows:
1 cycle of 95◦C for 10 min and 40 cycles of 95◦C for 15 s,
60◦C for 30 s and 72◦C for 30 s, representing the melt-
ing, primer annealing and primer extension phases of the
reaction, respectively. Following the amplification, a reac-
tion product melt curve was performed to provide evidence
for a single reaction product. The correctness was further
confirmed after denaturing agarose gel electrophoresis and
staining with ethidium bromide of the Q-PCR products. All
mRNA expression data were normalized with the β-actin
mRNA expression in the same sample.
Quantitative and qualitative evaluation of aorta
calcification
Vascular calcifications in the aortic root were evaluated
by von Kossa staining in 7 µm cryosections of the aortic
tissue. Briefly, the cryosections were placed in 5% silver ni-
trate solution (Sigma Aldrich, St. Louis, MO, USA) for 30
min in darkness. Then they were put in revelatory solution
(Kodak) for 5 min and fixed in 5% sodium-thiosulphate
solution for another 5 min. Finally, they were stained with
2% eosin. Calcium deposits appeared in black on bright
red-coloured surrounding tissue. We developed morpho-
logic image-processing algorithms for computer-assisted
automated quantitative measurement of calcification from
aortic sections revealed by von Kossa silver nitrate staining.
Data were expressed as the relative proportion of the calci-
fied area to the total surface area covering either the inside
or the outside of atherosclerotic lesions and as the size of
calcification granules on either surface, as described pre-
viously [29]. We performed statistical analyses in those
aortic root samples where we could obtain three visible
valves. In order to reduce the observed differences in ab-
solute vascular calcification values between the two differ-
ent mouse series, we elected to present these data relative
to each other after adjustment as follows. We considered
as 1 the percentage of vascular calcification found in the
mouse of the non-CRF group, which had the closest value
to the mean value of the group. Subsequently, the individual
values of each vascular calcification measurement from the
two experiments were adjusted by this value.
OPN protein expression in aortic root lesions
Snap frozen 7 µm sections were analysed by immunohisto-
chemical staining for OPN expression. Briefly, the sections
were fixed in acetone for 10 min. Endogenous peroxidase
was quenched with 2% H2O2 in methanol for 10 min, fol-
lowed by a brief rinse in PBS and incubation in 10% bovine
serum albumin (BSA) for 1 h. Polyclonal rabbit anti-mouse
OPN antibody (Assay Designs Inc., Ann Arbor, MI, USA)
was added in blocking buffer (1% BSA in PBS) in a 1:100
dilution and incubated at 4◦C overnight. After rinsing with
PBS, biotinylated goat anti-rabbit antibody (Vector Lab-
oratories) was added in blocking buffer in a dilution of
1:300 and incubated for 30 min at room temperature. Perox-
idase ABC-reagent and AEC (3-Amino-9-Ethyl-Carbazole)
chromogenic substrate were applied following a commer-
cial protocol (Vector Laboratories). The OPN expression
was analysed inside the atherosclerotic plaque lesions. The
representative image of each slide with visible three aortic
valves on a ×25 magnification was captured on a micro-
computer equipped with Sony Camera and Histolab soft-
ware (Microvision Instruments, Envy, France) and analysed
by computerized image analysis program. Semiquantative
assessment of OPN staining was done by quantification of
brown field expression inside of the three atherosclerotic
valve lesions of the aortic root, as previously described for
other proteins [24,30].
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Quantification of nitrotyrosine, monocyte-macrophage
(MOMA) infiltration and collagen in aortic root lesions
Lesion nitrotyrosine expression, a marker for oxidative
stress in atheromatous lesions and MOMA infiltration and
lesion collagen content were assessed as described previ-
ously [24]. Briefly, for nitrotyrosine analysis, the 7 µm
cryosections were preincubated in peroxidase blocking
solution (Dako Cytomation, Trappes, France) before incu-
bation with biotinylated nitrotyrosine monoclonal mouse
antibody (Cayman Chemical, SpiBio, Massy, France). The
sections were treated with peroxidase-labeled streptavidin
(Dako) for 15 min, followed by reaction with diaminobenzi-
dine/hydrogen peroxidase. A representative image of each
slide with three aortic valves visible on a ×25 magnification
was captured on a microcomputer equipped with Sony
Camera and Histolab software (Microvision Instruments,
Envy, France) and analysed by computerized image anal-
ysis program. Semiquantative assessment of nitrotyrosine
expression was done by semiautomatic quantification of
brown field expression specifically inside of the atheroscle-
rotic valve lesions, as described previously [24,30].
For MOMA infiltration, aortic 7 µm cryosections were
incubated with 10% normal goat serum at room tempera-
ture, and incubated with a primary rat monoclonal antibody
against mouse macrophages (clone MOMA-2; BioSource
International, Camarillo, CA, USA). The secondary anti-
body was a biotin-horseradish peroxidase-conjugated goat
anti-rat IgG (Vector Laboratories, Biovalley, Marne la
Valle´e, France). Immunostainings were visualized after
incubation with a peroxidase detection system (Vectastain
ABC kit, Vector Laboratories) using 3-amino 9-ethyl
carbazole (Sigma Aldrich) as substrate. Data were analysed
as the relative proportion of infiltrated area to lesion total
surface area as described previously [29].
The aortic root collagen content in atheromatous lesions
was determined by Sirius red staining [25,31] in all aortic
roots where three valves were observed. Images of the best
aortic root section with three visible aortic valves were
captured and analysed as above. We measured the surface
of the atherosclerotic lesions in all three valves, and then,
the collagen surface stained as red-coloured fields inside
the plaque lesions. Results have been expressed as the
relative proportion of collagen area to total surface area
of atherosclerotic lesions.
Statistical analysis
Data were evaluated by analysis of variance (ANOVA),
Mann–Whitney test or chi-square test, as appropriate. Re-
sults were expressed as means ± SEM. Differences between
groups were considered significant for p < 0.05.
Results
Serum biochemistry
At the time of sacrifice (10 weeks of CRF and 8 weeks of
diet), mean body weight was decreased in the CRF mice
supplemented with CaCO3 diet compared with non-CRF
mice on standard diet. There was no difference between
non-CRF and CRF mice on standard diet (Table 1). Serum
urea, total cholesterol and calcium concentrations were sig-
nificantly increased in both CRF groups, compared with the
non-CRF groups (Table 1). CaCO3 treatment was effective
in decreasing serum phosphorus in CRF mice although it
was associated with a higher serum calcium concentration
than in non-Ca-supplemented CRF mice (Table 1). There
was a numerical reduction of serum Ca × P product by
the CaCO3 treatment. However, this decrease was not sig-
nificant (ANOVA global p value, 0.063). Serum PTH was
numerically lower in CRF mice on CaCO3 diet than in CRF
control mice, and comparable to those in non-CRF mice.
Unfortunately, only a small number of serum PTH levels
measured in CRF mice on CaCO3 diet fell within the limits
of the PTH kit used. Our efforts to obtain additional PTH
data in the supplementary mouse series, including the use
of another kit, remained unsuccessful.
Aorta calcification
We observed two different types of vascular calcification:
(i) a solid type of deposit, with one large compact black
deposit inside the plaque (Figure 1A) and (ii) another type
of deposit with more diffused, punctuated black deposits
dispersed throughout the lesion area (Figure 1B and C). We
found no relation of the type of deposits with the presence
or absence of CRF or with the type of treatment.
Both, plaque and non-plaque vascular calcification were
increased in CRF mice compared with non-CRF littermates
Table 1. Effect of CaCO3 supplemented diet on body weight and serum biochemistry
Non-CRF standard dieta CRF standard dietb CRF CaCO3 dietc p
Body weight g (n, 20/20/20) 25.7 ± 0.9 24.0 ± 0.4 23.2 ± 0.4a <0.05
Urea, mmol/l (n, 19/17/16) 8.9 ± 0.3 27.0 ± 1.2a 25.0 ± 1.4a <0.0001
Calcium, mmol/l (n, 18/18/16) 2.32 ± 0.03 2.54 ± 0.05a 2.67 ± 0.06a,b <0.0001
Phosphorus, mmol/l (n, 17/17/16) 2.75 ± 0.26 2.84 ± 0.18 2.05 ± 0.18a,b <0.05
Ca × P, mmol2/l2 (n, 17/17/16) 6.30 ± 0.58 7.16 ± 0.49 5.40 ± 0.45 0.063
PTH, ng/ml∗ (n, 9/6/3) 39 ± 9 124 ± 29 26 ± 7
Total cholesterol, mmol/l (n, 17/15/15) 11.2 ± 0.3 15.3 ± 0.6a 13.9 ± 0.6a <0.0001
CRF indicates chronic renal failure. Data were analysed by ANOVA (means ± SEM), p stands for global p of ANOVA. Treatment groups: non-CRF on
standard diet, CRF on standard diet and CRF on CaCO3 supplemented diet, n is the number of mice. Superscript letters show significant difference to
corresponding group (p < 0.05). ∗Serum PTH could be measured in limited number of mice.
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Table 2. Effect of CaCO3 supplementation on thoracic aorta plaque area and plaque-associated collagen content and OPN expression at aortic root site
Non-CRF standard dieta CRF standard dietb CRF CaCO3 dietc p
Thoracic aorta lesion area % (n, 9/11/11) 0.52 ± 0.06 1.16 ± 0.17a 0.80 ± 0.16 <0.05
Plaque collagen content % (n, 9/9/9) 42.4 ± 2.2 55.2 ± 2.6a 55.7 ± 2.9a <0.001
Mice with positive OPN staining % (n, 6/8/6) 50 12.5 83.3b <0.03
CRF indicates chronic renal failure. Data were analysed by ANOVA for plaque area and for collagen content (means ± SEM) and by Chi-square test
for OPN, p stands for global p. Treatment groups: non-CRF on standard diet, CRF on standard diet and CRF on CaCO3 supplemented diet, n is the
number of mice. Superscript letters show significant difference to corresponding group (p < 0.05).
A B C
FED
Fig. 1. (A–C) Extent and localization of different types of atherosclerotic lesion calcification in apoE−/− mice without CRF receiving standard
diet or in apoE−/− mice with CRF receiving either CaCO3 supplemented diet or standard control diet. von Kossa staining: (A) solid type of plaque
calcification, magnification ×25; (B) non-plaque calcification, magnification ×25; (C) diffuse type of plaque calcification, magnification ×100. (D–F)
Immunohistochemical visualization of osteoprotegerin (OPN) protein expression in apoE−/− mice without CRF receiving standard diet or in apoE−/−
mice with CRF receiving either CaCO3 supplemented diet or standard control diet. (D) CRF mice on standard diet, with three visible aortic valvules
and low OPN expression (brown) in only one of the valvular lesions, magnification ×25; (E) CRF mice on CaCO3 diet, with three visible valvules and
marked OPN expression (dark brown) in all three valvular lesions, magnification ×25; (F) OPN expression in aortic root valve lesion in CRF mice on
CaCO3 diet, magnification ×100.
(Figures 2A, B and C). CaCO3 supplementation induced a
significant decrease in both types of calcification, compa-
red with no CaCO3 supplementation (Figures 2A, B
and C).
Aortic atheromatous lesions and gene expression
In the CRF mice, atherosclerotic lesions on the longitudinal
aorta were increased, compared with non-CRF littermates.
The administration of a CaCO3 diet did not significantly
change the extent of atherosclerotic lesions in CRF mice
(Table 2).
For the assessment of possible differences of aortic gene
expression between non-CRF and CRF mice on normal diet
or on CaCO3 supplemented diet (Figure 3), we analyzed
aortic tissues from the aortic root down to the abdominal
part of the aorta using Q-PCR. There was a significant
increase of OPG gene expression in both CRF mouse
groups, compared with the non-CRF mice. The numerical
increase in CRF mice in response to CaCO3 supplementa-
tion, compared with CRF mice on standard diet, however,
did not reach the level of statistical significance (Figure 3).
As to OPN, there was no difference in its gene expression
between non-CRF and CRF mice on standard diet. Al-
though CaCO3 supplementation of CRF mice enhanced its
expression by two-fold compared with CRF mice on stan-
dard diet, this difference was not significant. The difference
of OPN expression between CRF CaCO3 mice and control
mice on standard diet also was not significant.
OPN protein expression in atherosclerotic lesions of the
aortic root
By immunostaining, OPN expression in aortic root lesions
was increased in CRF mice on CaCO3 diet, compared
to CRF mice (Figure 1D) on standard diet (Table 2 and
Figure 1E and F). There was no difference between the two
CRF and non-CRF control groups.
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Fig. 2. (A) Plaque calcifications in apoE−/− mice without CRF receiving standard diet or in apoE−/− mice with CRF receiving either CaCO3
supplemented diet or standard control diet. Values at the time of sacrifice reflecting the proportion of calcified plaque area to the total surface area of
atherosclerotic lesions in apoE−/− mice. Analysis by ANOVA. (B) Non-plaque calcifications in apoE−/− mice without CRF receiving standard diet
or in apoE−/− mice with CRF receiving either CaCO3 supplemented diet or standard diet. Values at the time of sacrifice reflecting the proportion of
calcified non-plaque area to the total surface area outside of atherosclerotic lesions in apoE−/− mice. Analysis by ANOVA. (C) Plaque and non-plaque
aortic calcifications in apoE−/− mice without CRF receiving standard diet or in apoE−/− mice with CRF receiving either CaCO3 supplemented diet or
standard diet. Values at the time of sacrifice reflecting the proportion of plaque and non-plaque associated calcified area together versus total surface
area. Analysis by ANOVA.
Fig. 3. Patterns of aortic gene expression of OPN and OPG in apoE−/− mice without CRF receiving standard diet or in apoE−/− mice with CRF
receiving either CaCO3 supplemented diet or standard diet. Aortic gene expression was determined with Q-PCR. n is the number of aortas analysed in
each group. Analysis by Mann–Whitney test.
Nitrotyrosine expression, MOMA infiltration and collagen
content in aortic lesions
CaCO3 diet did not lead to a reduction in nitrotyrosine
expression in atheromatous plaques, as compared to non-
CRF and CRF control mice (data not shown). The percent-
age of cross-sectional lesion area occupied by macrophages,
as revealed by MOMA-2 staining, was also comparable for
the three non-CRF and CRF mice groups (data not shown).
Finally, collagen content was significantly increased in both
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CRF mouse groups compared to non-CRF mice. CaCO3
supplementation did not induce a change of collagen
content (Table 2).
Discussion
In the present study, we unexpectedly found an inhibitory
effect of CaCO3 on the lesion severity in both plaque
(‘intima’) and non-plaque (‘media’) calcification in our
experimental model of CRF apoE−/− mice. This inhibitory
effect occurred despite an increase in serum calcium
concentration. Serum phosphorus concentration decreased
significantly although the Ca × P product remained un-
changed. The inhibitory effect was associated with a
two-fold increase of OPN gene expression in total aorta
(not statistically significant) and a significant increase in
OPN protein expression in aortic lesion areas, compared
with control CRF mice. We did not find evidence of changes
in local markers of inflammation (MOMA-2 staining) or
oxidative stress (nitrotyrosine expression) in response to the
CaCO3 treatment. Finally, the degree of aorta atheroscle-
rosis did not differ between Ca-supplemented and control
CRF mice.
The present results are not in accord with the general
assumption that the high intestinal calcium absorption
subsequent to the ingestion of large amounts of calcium-
containing phosphate binders necessarily promotes vascu-
lar calcification, even in the absence of hypercalcaemia
[22,32]. They, therefore, appear to be at variance with
several retrospective clinical studies which showed a cor-
relation between cumulative oral calcium load and vascu-
lar calcification among CKD patients receiving CaCO3 or
calcium acetate treatment [17,33]. Of note, the association
of calcium-based phosphate binders with active vitamin
D derivates for the treatment of secondary hyperparathy-
roidism may further enhance intestinal calcium absorption,
and in addition that of phosphate, and cause an
oversuppression of parathyroid gland function [34].
In the CRF apoE−/− mice of the present study, CaCO3
induced a decrease of serum phosphorus concentration in
CRF mice on CaCO3 diet compared with non-calcium-
supplemented mice, although serum calcium and Ca × P
product were increased. Unfortunately, we were unable to
measure serum 1,25-diOH-vitamin D due to insufficient
availability of blood at the time of sacrifice. It is of note
that our CRF model is characterized by a constant increase
in serum Ca and a variable increase in serum PTH, often in
the absence of an elevation of serum phosphorus, together
with a striking acceleration of atherosclerosis and vascular
calcification, compared with non-CRF mice [25,30]. Inter-
estingly, recent studies clearly demonstrated a major, active
role of phosphate in blood vessel calcification, both in vitro
[9,10,35] and in vivo [36,37]. Of particular importance, is
the observation by Murshed et al [38], who showed in a
gene knock-out animal model that two genes were nec-
essary, but also sufficient to trigger ectopic calcification,
namely TNAP, an enzyme that cleaves pyrophosphate into
two phosphate ions, and type I collagen.
In the present study, we were able to observe an inhibitory
effect of CaCO3 on vascular calcification at two different
sites of the aorta, namely within atheromatous lesions
and outside the lesions. Since serum calcium, which was
elevated in CRF mice without calcium supplementation, in-
creased to even higher levels in calcium-supplemented CRF
mice, the beneficial effect of CaCO3 on vascular calcifica-
tion could be explained, at least partially, by the improved
control of hyperphosphataemia.
An alternative explanation for the observed decrease in
vascular calcification by CaCO3 diet in this model could
be through an effect on calcification regulatory factors
expressed by vascular smooth muscle cells after their trans-
formation into osteoblast-like cells. These factors either
inhibit or promote the calcification process. OPN is one of
them. It is generally considered as an inhibitor of calcifi-
cation [9]. In the present study, we observed an increase
of plaque OPN protein expression at the aortic root site in
CRF mice on CaCO3 diet compared with CRF controls. We
also observed an up to two-fold increase of both OPN and
OPG gene expression in total thoracic aorta. However, this
increase was not significant, maybe due to the relatively
small number of aortas available for this analysis. Upreg-
ulation of OPN and OPG expression could be interpreted
as protective mechanisms against the observed increase in
vascular calcification in CRF mice. In line with this obser-
vation, Moe et al. recently demonstrated an increased ex-
pression of OPN in the medial layer of arteries from chronic
dialysis patients. Positive staining for OPN and other bone
matrix molecules was strongly correlated with medial cal-
cification [38]. Moreover, OPN was expressed in the intima
of calcified arteries of such patients [39]. Finally, the ad-
dition of uraemic serum also increased OPN expression in
bovine vascular smooth muscle cells in vitro [40]. Recently,
it was shown in another mouse model that calcification
of the vascular tissue was preceded by local induction of
OPN expression [41]. We have to point out that any failure
to observe significant changes in aortic protein and gene
expression could be due to either real absence of changes
or technical reasons, including the semiquantative nature of
immunohistochemistry methods used for the study of pro-
teins. Another problem that we faced was that of the PTH
measurements. The widely used so-called ‘mouse’ Intact
PTH ELISA was actually developed for studies in rats. Re-
sults obtained with this method in normal versus CRF mice
proved to be extremely heterogeneous.
CaCO3 did not reduce aortic plaque area, in contrast to
our previous demonstration of a decrease in the degree
of both calcification and atherosclerosis in response to
the phosphate binder sevelamer [30] and the calcimimetic
R-568 [42], respectively. One of the observed differences
between these studies is an increase in serum calcium in
response to CaCO3, as compared to no change in serum
calcium in response to sevelamer and a decrease in response
to R-568. Whether the difference in the degree of hypercal-
caemia plays any role in the development of atherosclerosis
remains to be seen.
Since hyperphosphataemia also appears to play an
important role in vascular calcification, it is of interest to
note that a graded independent relation has been found
between increasing levels of serum phosphate and the
relative risk of cardiovascular events and death both in pa-
tients with CKD [19,43] and in patients without CKD [44].
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The control of hyperphosphataemia by CaCO3 probably is
better than the absence of such control, at least in terms
of vascular calcification, as shown in the present study
and the study by Cozzolino et al. [45]. These authors also
observed a decrease in aorta calcification in response to
CaCO3 administration. However, CaCO3 is probably less
potent than the calcium-free phosphate binder sevelamer
in retarding vascular disease progression and improving
survival, as suggested by a recent controlled study in inci-
dent haemodialysis patients comparing calcium-containing
phosphate binders with sevelamer [23].
In conclusion, CaCO3 given for the control of
hyperphosphataemia in CRF does not necessarily enhance
the progression of arterial calcification, compared with un-
controlled hyperphosphataemia. Based on our present ob-
servation in a CRF mouse model, it may even exert a pro-
tective effect, at least in presence of an increased Ca × P
product. Our finding is compatible with a more important
role of phosphorus than of calcium in promoting vascular
calcification in the setting of CRF.
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